1. Latar belakang klinis
Gambaran penyakit
Uraian berikut tersedia dalam bahasa Inggris.
Tobacco dependence is a chronic, relapsing nicotine-dependence disorder and the leading preventable cause of premature death worldwide, causally linked to cardiovascular disease (ischaemic heart disease, stroke), chronic obstructive pulmonary disease, at least 15 cancers (including lung cancer), and adverse pregnancy outcomes. Nicotine sustains dependence by activating alpha-4-beta-2 (alpha4beta2) neuronal nicotinic acetylcholine receptors in the mesolimbic dopaminergic reward pathway, driving the craving and withdrawal that make unaided quit attempts fail in over 95% of cases; most smokers therefore require repeated attempts, and effective treatment combines pharmacotherapy with behavioural support. Varenicline (ATC N07BA03), a selective alpha4beta2 partial agonist, simultaneously relieves withdrawal and craving while blocking nicotine's reinforcing effects, addressing the neurobiology of dependence directly. Cessation at any age confers substantial mortality benefit, with risk reversal beginning within weeks of abstinence and increasing the earlier a smoker quits (WHO Tobacco fact sheet; NICE TA123, 2007; Cahill et al., Cochrane 2013, PMID 23728690).
Epidemiologi
Uraian berikut tersedia dalam bahasa Inggris.
Globally an estimated 1.3 billion people use tobacco, and tobacco kills more than 7 million users plus an estimated 1.6 million non-smokers exposed to second-hand smoke each year, with around 80% of users living in low- and middle-income countries; prevalence is declining globally but rising in a handful of countries including Indonesia (WHO Tobacco fact sheet; WHO global tobacco trends report 2025). Indonesia carries one of the world's heaviest burdens: Riskesdas 2018 (Kemenkes) recorded adult (15+) male smoking prevalence of approximately 62-63% (about 62.9%), the highest male prevalence in Southeast Asia, versus roughly 2.7% in females, with district-level male prevalence ranging from 9% to 81% across districts (Hapsari et al., Global Journal of Health Science 2020). The earlier ~67% figure sometimes cited reflects Riskesdas 2013, not 2018. The most current national survey, SKI 2023 (Survei Kesehatan Indonesia), reports that approximately 28.6% (28.62%) of those aged 15 and over smoke, equating to roughly 70 million active smokers, with continued rise among youth. GBD 2019 attributed more than 290,000 Indonesian deaths to tobacco, nearly 17% of all deaths; a more recent GBD 2021 estimate of about 268,614 smoking-attributable deaths has also been reported (IHME GBD; PLOS One 2020).
Terapi standar saat ini
Uraian berikut tersedia dalam bahasa Inggris.
Standard cessation care combines behavioural support (brief advice, counselling, quitlines) with first-line pharmacotherapy. Three classes are licensed in Europe and the USA, nicotine replacement therapy (NRT, patches/gum/lozenge), bupropion, and varenicline, each used as part of a behavioural-support programme, with behavioural support alone as the floor of care; cytisine, a low-cost partial agonist long marketed as Tabex, is licensed in some countries and is an emerging affordable alternative of particular relevance to low- and middle-income settings (Cahill et al., Cochrane 2013, PMID 23728690; West et al., NEJM 2011). Network meta-analytic evidence ranks varenicline as the single most effective monotherapy: it increased the odds of sustained abstinence versus placebo (OR 2.88), and was superior to single-form NRT (OR 1.57) and to bupropion (OR 1.59), while comparable to combination NRT (Cahill 2013). The standard varenicline regimen is a 12-week course, started 1-2 weeks before a set quit date and titrated to 1 mg twice daily (NICE TA123, 2007). In Indonesia, the available behavioural backbone is delivered through Upaya Berhenti Merokok (UBM) clinics and the national Quitline (0800-177-6565).
Status regulasi dan penjaminan
Uraian berikut tersedia dalam bahasa Inggris.
Varenicline (originator Champix/Chantix, Pfizer) received US FDA approval in 2006 and EMA marketing authorisation the same year as a prescription smoking-cessation aid; generic varenicline now holds authorisation following the 2021 branded-supply withdrawal over a nitrosamine impurity. NICE appraised it in Technology Appraisal TA123 (published 25 July 2007), recommending it within its licensed indication as an option for smokers wishing to quit, normally only as part of a behavioural-support programme (NICE TA123). In Indonesia, varenicline (Champix) has held BPOM registration, but smoking-cessation pharmacotherapy is not a JKN priority: the Formularium Nasional (Fornas), which governs JKN-reimbursed medicines, comprised 677 active substances after the 2024 review and does not include cessation agents such as varenicline as a covered benefit, so access is largely out-of-pocket. Varenicline has also been studied locally, with an RCT at Persahabatan Hospital, Jakarta, demonstrating efficacy and good tolerability, underscoring that the inclusion gap is one of reimbursement and delivery rather than evidence (NICE TA123, 2007; Kemenkes Ditjen Farmalkes 2024; Jakarta Post 2018; Indrawati/Yunus, Jurnal Respirologi Indonesia 2017).
2. Hasil kasus dasar
| Strategi | Biaya terdiskonto | QALY terdiskonto | Tahun hidup |
|---|---|---|---|
| Vareniklin selama 12 minggu | Rp 61,1 juta | 15,914 | 30,89 |
| dukungan perilaku saja | Rp 62,3 juta | 15,731 | 30,66 |
| Selisih | -Rp 1,1 juta | 0,182 | - |
3. Analisis probabilistik
- Simulasi probabilistik (500 sampel)
- Kasus dasar
4. Analisis sensitivitas
- Parameter pada nilai rendah
- Parameter pada nilai tinggi
5. Analisis skenario
| Skenario | Selisih QALY | Selisih biaya | Rasio per QALY |
|---|---|---|---|
| Base case (40 yr, trial adherence) | 0,182 | -Rp 1,1 juta | Lebih efektif dan lebih hemat |
| 5-year horizon | 0,026 | Rp 858.399 | Rp 33,3 juta |
| 10-year horizon | 0,050 | Rp 417.389 | Rp 8,4 juta |
| 20-year horizon | 0,098 | -Rp 413.651 | Lebih efektif dan lebih hemat |
| Real-world adherence (quit rate ×0.65) | 0,098 | -Rp 121.172 | Lebih efektif dan lebih hemat |
| 0% discount rate (undiscounted) | 0,342 | -Rp 2,7 juta | Lebih efektif dan lebih hemat |
| 5% discount rate | 0,129 | -Rp 573.045 | Lebih efektif dan lebih hemat |
6. Validasi model
Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).
| Luaran pembanding | Prediksi model | Data terbit | Sumber |
|---|---|---|---|
| Lung cancer cumulative incidence (smoker, 40 yr) | 5,0% | 5,8% | Globocan 2020 Indonesia lung cancer age-standardized incidence × smoker RR ~5.6 (US Surgeon General Report) |
| COPD annual incidence (smoker) | 0,5% | 0,5% | Riskesdas 2018 chronic respiratory disease prevalence × incidence proxy |
| Cardiovascular disease annual incidence (smoker age 45+) | 1,4% | 1,4% | Survei Kesehatan Indonesia 2023 + INA-Heart registry baseline |
| All-cause mortality 20-yr (smoker age 45-65) | 22,4% | 19,4% | IDI 2022 life table smoker hazard ratio applied to age-specific Indonesian mortality |
7. Penyesuaian untuk Indonesia
Uraian berikut tersedia dalam bahasa Inggris.
- Threshold: WHO-CHOICE proxy 1× PDB Rp 75jt/QALY; 3× PDB Rp 225jt/QALY
- Drug cost: generic varenicline post-2020, Indian sourcing ~Rp 1-1.5jt per 12-wk course
- Counselling infrastructure: Puskesmas UBM (Upaya Berhenti Merokok) tier-1 coverage uneven luar Jawa, adaptation risk
- Cultural context: family smoking + warung kopi patterns may differ from UK adherence/relapse profile
- Eligible population: Riskesdas 2023 = 70 juta perokok aktif Indonesia. Even 1% annual quit attempt = 700k eligible/yr.